7-phenylpteridine-2,4-diol | 1009303-72-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 蝶啶及其衍生物
• 英文名称: 7-phenylpteridine-2,4-diol
• 英文别名: 2,4-dichloro-7-phenyl-pteridine；2,4-Dichloro-7-phenylpteridine；2,4-dichloro-7-phenylpteridine
• CAS: 1009303-72-3
• 化学式: C₁₂H₆Cl₂N₄
• 分子量: 277.112
• InChiKey: DLMZJIAYFJUGMF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.4
• 重原子数：
  18
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  51.6
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  7-phenylpteridine-2,4-diol 在 N,N-二异丙基乙胺 作用下， 以 二氯甲烷 、 N,N-二甲基乙酰胺 为溶剂， 生成 (2S,6R)-2,6-dimethyl-4-[4-[(3S)-3-methylmorpholin-4-yl]-7-phenylpteridin-2-yl]morpholine
  参考文献：
  名称：

  Optimization of potent and selective dual mTORC1 and mTORC2 inhibitors: The discovery of AZD8055 and AZD2014

  摘要：

  The optimization of a potent and highly selective series of dual mTORC1 and mTORC2 inhibitors is described. An initial focus on improving cellular potency whilst maintaining or improving other key parameters, such as aqueous solubility and margins over hERG IC50, led to the discovery of the clinical candidate AZD8055 (14). Further optimization, particularly aimed at reducing the rate of metabolism in human hepatocyte incubations, resulted in the discovery of the clinical candidate AZD2014 (21). (C) 2013 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2013.01.019
• 作为产物：
  描述：

  7-Phenyllumazin 在 N,N-二异丙基乙胺 、 三氯氧磷 作用下， 以 甲苯 为溶剂， 生成 7-phenylpteridine-2,4-diol
  参考文献：
  名称：

  Optimization of potent and selective dual mTORC1 and mTORC2 inhibitors: The discovery of AZD8055 and AZD2014

  摘要：

  The optimization of a potent and highly selective series of dual mTORC1 and mTORC2 inhibitors is described. An initial focus on improving cellular potency whilst maintaining or improving other key parameters, such as aqueous solubility and margins over hERG IC50, led to the discovery of the clinical candidate AZD8055 (14). Further optimization, particularly aimed at reducing the rate of metabolism in human hepatocyte incubations, resulted in the discovery of the clinical candidate AZD2014 (21). (C) 2013 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2013.01.019

文献信息

• Pyrido-, Pyrazo- and Pyrimido-Pyrimidine Derivatives as mTOR Inhibitors
  申请人：Hummersone Marc Geoffrey

  公开号：US20080194546A1

  公开（公告）日：2008-08-14

  There is provided a compound of formula I: wherein: one or two of X 5 , X 6 and X 8 is N, and the others are CH; R 7 is selected from halo, OR O1 , SR S1 , NR N1 R N2 , NR N7a C(═O)R C1 , NR N7b SO 2 R S2a , an optionally substituted C 5-20 heteroaryl group, or an optionally substituted C 5-20 aryl group, where R O1 and R S1 are selected from H, an optionally substituted C 5-20 aryl group, an optionally substituted C 5-20 heteroaryl group, or an optionally substituted C 1-7 alkyl group; R N1 and R N2 are independently selected from H, an optionally substituted C 1-7 alkyl group, an optionally substituted C 5-20 heteroaryl group, an optionally substituted C 5-20 aryl group or R N1 and R N2 together with the nitrogen to which they are bound form a heterocyclic ring containing between 3 and 8 ring atoms; R C1 is selected from H, an optionally substituted C 5-20 aryl group, an optionally substituted C 5-20 heteroaryl group, an optionally substituted C 1-7 alkyl group or NR N8 R N9 , where R N8 and R N9 are independently selected from H, an optionally substituted C 1-7 alkyl group, an optionally substituted C 5-20 heteroaryl group, an optionally substituted C 5-20 aryl group or R N8 and R N9 together with the nitrogen to which they are bound form a heterocyclic ring containing between 3 and 8 ring atoms; R S2a is selected from H, an optionally substituted C 5-20 aryl group, an optionally substituted C 5-20 heteroaryl group, or an optionally substituted C 1-7 alkyl group; R N7a and R N7b are selected from H and a C 1-4 alkyl group; R N3 and R N4 , together with the nitrogen to which they are bound, form a heterocyclic ring containing between 3 and 8 ring atoms; R 2 is selected from H, halo, OR O2 , SR S2b , NR N5 R N6 , an optionally substituted C 5-20 heteroaryl group, and an optionally substituted C 5-20 aryl group, wherein R O2 and R S2b are selected from H, an optionally substituted C 5-20 aryl group, an optionally substituted C 5-20 heteroaryl group, or an optionally substituted C 1-7 alkyl group; R N5 and R N6 are independently selected from H, an optionally substituted C 1-7 alkyl group, an optionally substituted C 5-20 heteroaryl group, and an optionally substituted C 5-20 aryl group, or R N5 and R N6 together with the nitrogen to which they are bound form a heterocyclic ring containing between 3 and 8 ring atoms, or a pharmaceutically acceptable salt thereof, with the proviso that when R 2 is unsubstituted morpholino. R N3 and R N4 together with the nitrogen atom to which they are attached form an unsubstituted morpholino and R 7 is unsubstituted phenyl, and X 5 is CH, then X 6 is not N and X 8 is not CH, or X 6 is not CH and X 8 is not N, and when R 2 is unsubstituted piperidinyl, R N3 and R N4 together with the nitrogen atom to which they are attached form an unsubstituted piperidinyl and R 7 is unsubstituted phenyl, and X 5 is CH, then X 6 is not CH and X is not N. There are also provided processes for the manufacture of a compound of Formula 1, and the use of a compound of Formula 1 as a medicament and in the treatment of cancer.

  提供了一种化合物，其化学式为I：其中：X5、X6和X8中的一个或两个是N，其余为CH；R7选自卤素、ORO1、SRS1、NRN1RN2、NRN7aC（═O）RC1、NRN7bSO2RS2a、可选取代的C5-20杂环芳基基团或可选取代的C5-20芳基基团，其中RO1和RS1选自H、可选取代的C5-20芳基基团、可选取代的C5-20杂环芳基基团或可选取代的C1-7烷基基团；RN1和RN2独立选自H、可选取代的C1-7烷基基团、可选取代的C5-20杂环芳基基团、可选取代的C5-20芳基基团或RN1和RN2与它们所连接的氮原子一起形成含有3至8个环原子的杂环环；RC1选自H、可选取代的C5-20芳基基团、可选取代的C5-20杂环芳基基团、可选取代的C1-7烷基基团或NRN8RN9，其中RN8和RN9独立选自H、可选取代的C1-7烷基基团、可选取代的C5-20杂环芳基基团、可选取代的C5-20芳基基团或RN8和RN9与它们所连接的氮原子一起形成含有3至8个环原子的杂环环；RS2a选自H、可选取代的C5-20芳基基团、可选取代的C5-20杂环芳基基团或可选取代的C1-7烷基基团；RN7a和RN7b选自H和C1-4烷基基团；RN3和RN4与它们所连接的氮原子一起形成含有3至8个环原子的杂环环；R2选自H、卤素、ORO2、SRS2b、NRN5RN6、可选取代的C5-20杂环芳基基团和可选取代的C5-20芳基基团，其中RO2和RS2b选自H、可选取代的C5-20芳基基团、可选取代的C5-20杂环芳基基团或可选取代的C1-7烷基基团；RN5和RN6独立选自H、可选取代的C1-7烷基基团、可选取代的C5-20杂环芳基基团和可选取代的C5-20芳基基团，或RN5和RN6与它们所连接的氮原子一起形成含有3至8个环原子的杂环环，或其药学上可接受的盐，但当R2为未取代的吗啡啶基时，RN3和RN4与它们所连接的氮原子一起形成未取代的吗啡啶基，R7为未取代的苯基，且X5为CH时，X6不是N且X8不是CH，或X6不是CH且X8不是N，当R2为未取代的哌啶基时，RN3和RN4与它们所连接的氮原子一起形成未取代的哌啶基，R7为未取代的苯基，且X5为CH时，X6不是CH且X不是N。还提供了制造化合物I的方法，以及将化合物I用作药物治疗癌症的用途。
• Novel Compounds
  申请人：Duggan Mary Ellen Heather

  公开号：US20080081809A1

  公开（公告）日：2008-04-03

  There is provided a compound of formula I: , or a pharmaceutically acceptable salt thereof. There are also provided processes for the manufacture of a compound of Formula 1, and the use of a compound of Formula 1 as a medicament and in the treatment of cancer.

  提供了一个公式I的化合物，或其药学上可接受的盐。还提供了制备公式1化合物的过程，以及将公式1化合物用作药物和治疗癌症的用途。
• Pyrido-, pyrazo- and pyrimido-pyrimidine derivatives as mTOR inhibitors
  申请人：KuDOS Pharmaceuticals Limited

  公开号：US10034884B2

  公开（公告）日：2018-07-31

  There is provided a compound of formula I: or a pharmaceutically acceptable salt thereof. There are also provided processes for the manufacture of a compound of Formula 1, and the use of a compound of Formula 1 as a medicament and in the treatment of cancer.

  本发明提供了一种式 I 的化合物： 或其药学上可接受的盐。此外，还提供了式 1 化合物的生产工艺，以及式 1 化合物作为药物和治疗癌症的用途。
• WO2008/23161
  申请人：——

  公开号：——

  公开（公告）日：——
• US7902189B2
  申请人：——

  公开号：US7902189B2

  公开（公告）日：2011-03-08